Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod Phase 3 in Ulcerative Colitis (Asia)
NCT04176588Phase 3Active, not recruiting
- Sponsor
- Everstar Medicines (Shanghai) Limited
- Start
- Sep 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etrasimod in ulcerative colitis (UC) (3 arms), sponsored by Everstar Medicines (Shanghai) Limited. Primary endpoint: Proportion of Subjects With Clinical Remission Assessed by modified Mayo score at 12 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04176588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176588.